ASX:IPD ImpediMed (IPD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About ImpediMed Stock (ASX:IPD) 30 days 90 days 365 days Advanced Chart Get ImpediMed alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.62 million shsAverage VolumeN/AMarket Capitalization$103.31 millionP/E RatioN/ADividend Yield3.28%Price TargetN/AConsensus RatingN/A Company OverviewImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.Read More… Receive IPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImpediMed and its competitors with MarketBeat's FREE daily newsletter. Email Address IPD Stock News HeadlinesIs ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?May 21, 2025 | finance.yahoo.comHealth Check: Impedimed says ‘nuts’ to tariffs as it squirrels away componentsApril 30, 2025 | msn.comBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.May 27, 2025 | Crypto 101 Media (Ad)ImpediMed Achieves Record Revenue and Strengthens Sales LeadershipApril 29, 2025 | tipranks.comImpediMed Director Increases Stake with Share-Based CompensationApril 28, 2025 | tipranks.comImpediMed to Release Quarterly Results and Host Investor CallApril 16, 2025 | tipranks.comImpediMed Unaffected by New U.S. TariffsApril 9, 2025 | tipranks.com“Accelerate Action” to boost women’s leadership in Aussie healthcare sectorMarch 7, 2025 | msn.comSee More Headlines IPD Stock Analysis - Frequently Asked Questions What other stocks do shareholders of ImpediMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImpediMed investors own include Bardoc Gold (BDC) and Appen (APX). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:IPD CIKN/A Webwww.impedimed.com Phone61 7 3860 3700FaxN/AEmployees76Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-102.5Net Income-$19.79 million Net Margins-191.78% Pretax MarginN/A Return on Equity-43.15% Return on Assets-25.96% Debt Debt-to-Equity Ratio2.81 Current Ratio6.33 Quick Ratio6.23 Sales & Book Value Annual Sales$10.32 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.60 Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares2,020,000,000Free FloatN/AMarket Cap$103.31 million OptionableNot Optionable Beta2.86 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (ASX:IPD) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImpediMed Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ImpediMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IPD Stock Free IPD Stock Alerts